Innovative diagnostic techniques for multidrug-resistant tuberculosis: A review of current and emerging technologies

Umesh Patil and Dr. Sujatha Vijaykumar

DOI: https://doi.org/10.33545/26641658.2024.v6.i2a.186

Abstract
Multidrug-resistant tuberculosis (MDR-TB) poses a significant challenge to global health, necessitating rapid and accurate diagnostic methods to ensure timely treatment and control. This review explores the current and emerging diagnostic technologies for MDR-TB, emphasizing their principles, advantages, and limitations.

Keywords: Multidrug-resistant tuberculosis, diagnostic techniques, current and emerging technologies

Introduction
Multidrug-resistant tuberculosis (MDR-TB) is defined as tuberculosis (TB) that is resistant to at least isoniazid and rifampicin, the two most potent anti-TB drugs. MDR-TB complicates treatment protocols and exacerbates the burden on healthcare systems, particularly in low-income countries. Rapid and accurate diagnosis is critical for effective management and containment of MDR-TB. This review delves into the current and emerging diagnostic technologies, highlighting advancements that promise to improve the detection and treatment outcomes of MDR-TB.

Current Diagnostic Techniques

Culture-Based Methods
Culture-based methods, considered the gold standard for TB diagnosis, involve growing Mycobacterium tuberculosis from patient samples. Techniques include:

- **Lowenstein-Jensen (LJ) Media:** Traditional solid media that can take up to 8 weeks for visible colony formation. It's reliable but slow, delaying treatment initiation.
- **BACTEC MGIT 960:** A liquid culture system that uses fluorescence to detect bacterial growth, significantly reducing detection time to about 7-14 days.

Advantages

- High sensitivity and specificity.
- Ability to perform drug susceptibility testing (DST).

Limitations

- Time-consuming.
- Requires biosafety facilities and skilled personnel.

Molecular Methods
Molecular diagnostic methods have revolutionized TB diagnosis by providing rapid results. Key technologies include:

- **Xpert MTB/RIF:** A nucleic acid amplification test (NAAT) that detects M. tuberculosis and rifampicin resistance directly from sputum samples in under 2 hours.
Advantages
- High sensitivity and specificity.
- Rapid results.
- Minimal biosafety requirements.

Limitations
- High cost.
- Limited to rifampicin resistance detection.

Line Probe Assays (LPAs): Detect genetic mutations associated with drug resistance. Examples include the GenoType MTBDRplus and MTBDRsl assays, which identify resistance to rifampicin, isoniazid, and second-line drugs.

Advantages
- Detects multiple resistances.
- Rapid results (24-48 hours).

Limitations
- Requires technical expertise.
- Limited sensitivity in smear-negative samples.

Emerging Diagnostic Technologies

Whole Genome Sequencing (WGS)
Whole Genome Sequencing (WGS) offers comprehensive insights into the genetic makeup of M. tuberculosis, identifying all potential drug resistance mutations.

Advantages
- Comprehensive detection of resistance mutations.
- Provides epidemiological data for tracking transmission.

Limitations
- High cost and complexity.
- Requires bioinformatics infrastructure and expertise.

CRISPR-Based Diagnostics
CRISPR technology, known for its gene-editing capabilities, is being adapted for diagnostic purposes. CRISPR-based diagnostics for TB, such as the SHERLOCK and DETECTR platforms, utilize CRISPR-Cas systems to detect specific DNA sequences associated with drug resistance.

Advantages
- High specificity and sensitivity.
- Potential for rapid and point-of-care testing.

Limitations
- Still in experimental stages.
- Requires further validation for clinical use.

Nanotechnology-Based Approaches
Nanotechnology is being explored to enhance TB diagnostics. Nanoparticles can be engineered to detect TB biomarkers with high sensitivity.

Techniques include
- Nanoparticle-Based Biosensors: Detect TB antigens or DNA with high accuracy.
- Quantum Dots and Gold Nanoparticles: Used for signal amplification in various assay formats.

Discussion and Future Directions
The rapid evolution of diagnostic technologies for MDR-TB is promising, yet challenges remain. High costs, technical complexities, and the need for infrastructure improvements in low-resource settings are significant barriers. To address these challenges and maximize the impact of these technologies, several key areas need to be focused on:

Reducing Costs and Improving Accessibility of Advanced Diagnostics
One of the primary barriers to widespread adoption of advanced diagnostic techniques is their cost. Reducing the costs of these technologies will require:
- Innovative Funding Mechanisms: Governments, non-profit organizations, and international health agencies should collaborate to subsidize the costs of diagnostic tools, making them affordable for low-resource settings.
- Economies of Scale: Increasing production and distribution can lower per-unit costs. Investments in manufacturing capabilities and global supply chains are necessary.
- Public-Private Partnerships: Collaborations between public health entities and private companies can drive down costs through shared resources and expertise.

Integrating Novel Technologies into Existing Healthcare Frameworks
For new diagnostic technologies to be effective, they must be seamlessly integrated into existing healthcare systems. This includes:
- Compatibility with Current Systems: New technologies should be designed to work within the existing infrastructure to minimize disruptions.
- Training Healthcare Workers: Ensuring that healthcare workers are adequately trained to use new diagnostic tools is crucial for their successful implementation.
- Streamlined Workflows: Developing protocols that incorporate new diagnostics without overburdening healthcare providers is essential.
Ensuring Robust Validation and Standardization of Emerging Methods

To gain widespread acceptance and use, new diagnostic methods must undergo rigorous validation and standardization processes:

- **Clinical Trials:** Extensive field trials are necessary to establish the efficacy and reliability of new diagnostics in diverse settings.
- **Regulatory Approvals:** Accelerating the approval process while ensuring thorough evaluation by regulatory bodies can help bring effective diagnostics to market more quickly.
- **Quality Control Standards:** Establishing and adhering to strict quality control standards ensures consistency and reliability in diagnostic results.

Enhancing Training and Capacity-Building in Resource-Limited Settings

To fully leverage advanced diagnostics, resource-limited settings require significant capacity-building efforts:

- **Training Programs:** Comprehensive training programs for healthcare workers on the use of new diagnostic technologies are essential.
- **Infrastructure Development:** Investing in the infrastructure necessary to support advanced diagnostics, such as laboratories and biosafety facilities, is critical.
- **Community Engagement:** Educating communities about the importance of diagnostics and building trust in new technologies can improve uptake and adherence to testing and treatment protocols.

Conclusion

Innovative diagnostic techniques are crucial for the effective management of MDR-TB. While current methods provide reliable results, emerging technologies hold the promise of faster, more accurate, and accessible diagnostics. Continued investment and research in these areas are essential to combat the global threat of MDR-TB effectively.

References